Bethyl is now a part of Fortis Life Sciences. Learn more.

Overview of Cardiovascular

Jump to Antibodies

The goal of cardiovascular research is to understand the molecular mechanisms of cardiovascular disease (CVD) and to develop new strategies for its treatment and prevention. Atherosclerosis is a major component of CVD. In atherosclerosis, the development of plaques in arterial walls involves abnormal lipid metabolism and chronic inflammation. It is clear that the immune system plays a key role in this process. Related areas of research include identifying the genes that predict risk for atherosclerosis, and to understand the molecular basis of blood clot formation. Cardiovascular research also includes the study of the genetic abnormalities that cause inappropriate signaling within the damaged heart resulting from congestive heart failure, and the genes and molecular mechanisms that lead to the formation of the heart and blood vessels.

Bethyl’s cardiovascular portfolio consists of more than 4,700 antibodies. Our antibodies have been manufactured on-site by Bethyl scientists. Our rigorous validation process ensures that the antibody will work in the applications outlined on the datasheet. These applications include: Western blot, immunohistochemistry, immunoprecipitation, immunocytochemistry, flow cytometry, proximity ligation assay, and ChIP. A Bethyl antibody is first validated for specificity in immunoprecipitation and/or western blot and if it passes our team will validate the antibody for additional applications. Our products are backed with a 100% guarantee to work in your assay, when used in under the same conditions outlined on the product datasheet, which provides confident, reliable results.

Bethyl sells a wide variety of antibodies for the study of cardiovascular. Recent publications using our antibodies for studying cardiovascular include:

  • Examining how a non-coding RNA interacts with an important heart protein and helps protect against heart failure1
  • Identifying a genetic risk factor for heart failure in Caucasian patients being associated with a chloride channel protein2
  • Characterizing a protein signaling cascade that restricts heart growth in an effort to better promote healing and cellular regeneration3
  • Exploring how the mutation of TIEG1 in the heart confers protective effects, including faster cell proliferation and scar repair during heart disease4


Detection of human and mouse Cytoskeletal Actin by WB.

Detection of human and mouse Cytoskeletal Actin by WB. Antibody: Rabbit anti-Cytoskeletal Actin (A300-491A). Secondary: HRP-conjugated goat anti-rabbit IgG (A120-101P).

Detection of human CaMKK2 by WB of immunoprecipitates from 293T lysate.

Detection of human CaMKK2 by WB of immunoprecipitates from 293T lysate. Antibodies: Rabbit anti-CaMKK2 (A304-009A). Secondary: ReliaBLOT® reagents (WB120).

Detection of human Notch1 by WB of immunoprecipitates from HeLa lysate.

Detection of human Notch1 by WB of immunoprecipitates from HeLa lysate. Antibodies: Rabbit anti-Notch1 (A301-894A and A301-895A). Secondary: ReliaBLOT® reagents (WB120).


Below is the entire list of targets involved in cardiovascular research. Can’t find what you are looking for? Bethyl offers a custom antibody service.




1. Han P, Li W, Lin CH, Yang J, Shang C, Nuernberg ST, Jin KK, Xu W, Lin CY, Lin CJ, et al. 2014. A long noncoding RNA protects the heart from pathological hypertrophy. Nature. Oct 2;514(7520):102-106. [Bethyl antibody used: SUZ12 (A302-407A)]

2. Cappola TP, Matkovich SJ, Wang W, van Booven D, Li M, Wang X, Qu L, Sweitzer NK, Fang JC, Reilly MP, et al. 2011. Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. Proc Natl Acad Sci USA. Feb 8;108(6):2456-2461. [Bethyl secondary antibody used: Mouse IgG-heavy and light chain antibody (A90-117P)]

3. Ragni CV, Diguet N, Le Garrec JF, Novotova M, Resende TP, Pop S, Charon N, Guillemot L, Kitasato L, Badouel C, et al. 2017. Amotl1 mediates sequestration of the Hippo effector Yap1 downstream of Fat4 to restrict heart growth. Nat Comm. Feb 27;8:14582. [Bethyl antibody used: LATS1 (A300-478A)]

4. Cen M, Hu P, Cai Z, Fang T, Zhang J, Lu M. 2017. TIEG1 deficiency confers enhanced myocardial protection in the infarcted heart by mediating the Pten/Akt signalling pathway. Int J Mol Med. Mar;39(3):569-578. [Bethyl antibody used: TIEG1 (A302-015A)]